• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法布里病的一种非典型心脏表现源于GLA基因的一种新型病理变异。

An Atypical Cardiac Manifestation of Fabry Disease from a Novel Pathological Variant on the GLA Gene.

作者信息

Sarsam Luay, Arouni Amy, Mahfood Haddad Toufik, Onaiwu Cherry O, Erickson Christopher

机构信息

Cardiovascular Disease, Arnot Ogden Medical Center, Elmira, USA.

Cardiology, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, USA.

出版信息

Cureus. 2020 Mar 13;12(3):e7262. doi: 10.7759/cureus.7262.

DOI:10.7759/cureus.7262
PMID:32292674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7153810/
Abstract

Fabry disease (FD) is one of the most common lysosomal storage disorders and is caused by an X-linked progressive inborn error of metabolism in the alpha-galactosidase A (α-Gal A) gene. This leads to intracellular accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), throughout the body. The impact of this accumulation is seen across multiple cell lines and therefore can cause multisystem organ dysfunction. The phenotype of FD results from variants on the GLA gene which codes for α-Gal A production, and variants on this gene have been shown to be strongly related to unexplained or idiopathic cardiovascular disorders. This report describes a 36-year-old Caucasian male found to have left ventricular hypertrophy (LVH) followed by genetic testing because of his family history of sudden cardiac death which revealed a variant of unknown significance for the GLA gene. Further measurement of α-Gal A leukocyte activity showed low levels, which was diagnostic for FD. The index patient had an unusual non-classic phenotype in that his sole presenting symptom was asymptomatic LVH, he presented early, and had low α-Gal A leukocyte activity. Early detection and prompt treatment with enzyme replacement therapy can improve outcomes and decrease mortality. In the absence of known risk factors, non-classical FD should be strongly considered in patients with unexplained LVH and a family history of sudden cardiac death at a young age.

摘要

法布里病(FD)是最常见的溶酶体贮积症之一,由X连锁的α-半乳糖苷酶A(α-Gal A)基因进行性先天性代谢缺陷引起。这导致糖鞘脂,主要是球三糖神经酰胺(Gb3)在全身细胞内蓄积。这种蓄积的影响在多种细胞系中都有体现,因此可导致多系统器官功能障碍。FD的表型由编码α-Gal A生成的GLA基因变异引起,该基因的变异已被证明与不明原因或特发性心血管疾病密切相关。本报告描述了一名36岁的白种男性,因有心脏性猝死家族史,经基因检测发现左心室肥厚(LVH),检测结果显示GLA基因有一个意义不明的变异。进一步检测α-Gal A白细胞活性显示水平较低,确诊为FD。该索引患者具有不寻常的非典型表型,其唯一的症状是无症状LVH,发病早,且α-Gal A白细胞活性低。早期检测并及时进行酶替代治疗可改善预后并降低死亡率。在没有已知危险因素的情况下,对于不明原因LVH且有年轻时心脏性猝死家族史的患者,应高度怀疑非典型FD。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4364/7153810/bcbac48c3426/cureus-0012-00000007262-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4364/7153810/49fa810a6c3a/cureus-0012-00000007262-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4364/7153810/bcbac48c3426/cureus-0012-00000007262-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4364/7153810/49fa810a6c3a/cureus-0012-00000007262-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4364/7153810/bcbac48c3426/cureus-0012-00000007262-i02.jpg

相似文献

1
An Atypical Cardiac Manifestation of Fabry Disease from a Novel Pathological Variant on the GLA Gene.法布里病的一种非典型心脏表现源于GLA基因的一种新型病理变异。
Cureus. 2020 Mar 13;12(3):e7262. doi: 10.7759/cureus.7262.
2
Diagnosis and Screening of Patients with Fabry Disease.法布里病患者的诊断与筛查
Ther Clin Risk Manag. 2020 Jun 22;16:551-558. doi: 10.2147/TCRM.S247814. eCollection 2020.
3
Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study.中国左心室肥厚患者中Fabry病的筛查:一项多中心前瞻性研究。
ESC Heart Fail. 2024 Dec;11(6):4381-4389. doi: 10.1002/ehf2.15065. Epub 2024 Sep 3.
4
Anderson-Fabry disease: a multiorgan disease.安德森-法布里病:一种多系统疾病。
Curr Pharm Des. 2013;19(33):5974-96. doi: 10.2174/13816128113199990352.
5
Fabry disease and its cardiac involvement.法布里病及其心脏受累情况。
J Gen Fam Med. 2017 May 8;18(5):225-229. doi: 10.1002/jgf2.76. eCollection 2017 Oct.
6
The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy.亚洲法布里心肌病高危筛查研究2(ASIAN-FAME-2):左心室肥厚患者中法布里病的患病率
J Clin Med. 2024 Jul 2;13(13):3896. doi: 10.3390/jcm13133896.
7
Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.法布里病的不确定诊断:关于左心室肥厚且存在意义不明基因变异的成人患者诊断的共识推荐
Int J Cardiol. 2014 Dec 15;177(2):400-8. doi: 10.1016/j.ijcard.2014.09.001. Epub 2014 Sep 20.
8
2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.《2021年法布里病心脏表现的临床特征、诊断及临床管理TSOC专家共识》
Acta Cardiol Sin. 2021 Jul;37(4):337-354. doi: 10.6515/ACS.202107_37(4).20210601A.
9
Fabry disease: Definition, Incidence, Clinical presentations and Treatment Focus on cardiac involvement.法布里病:定义、发病率、临床表现及治疗 重点关注心脏受累情况。
Pak J Med Sci. 2022 Nov-Dec;38(8):2337-2344. doi: 10.12669/pjms.38.8.7063.
10
Rare Etiology of Renal Failure in a 25-Year-Old Caucasian Man: Fabry Disease With a Novel Mutation of GLA Gene.一名25岁白种男性肾衰竭的罕见病因:伴有GLA基因新突变的法布里病
Cureus. 2020 Jul 11;12(7):e9136. doi: 10.7759/cureus.9136.

本文引用的文献

1
Left ventricular hypertrophy in athletes and hypertensive patients.运动员和高血压患者的左心室肥厚
J Clin Hypertens (Greenwich). 2017 Apr;19(4):413-417. doi: 10.1111/jch.12977. Epub 2017 Mar 1.
2
Discrimination of the "Athlete's Heart" from real disease by electrocardiogram and echocardiogram.通过心电图和超声心动图鉴别“运动员心脏”与实际疾病。
Cardiol Young. 2017 Jan;27(S1):S80-S88. doi: 10.1017/S1047951116002286.
3
Wolff-Parkinson-White and left ventricular noncompaction in a Fabry patient: A case report.法布里病患者合并预激综合征和左心室心肌致密化不全:一例报告
Turk Kardiyol Dern Ars. 2016 Apr;44(3):248-50. doi: 10.5543/tkda.2015.92800.
4
Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance.法布里病的诊断困境:关于临床意义不明的GLA突变的病例系列研究
Clin Genet. 2015 Aug;88(2):161-6. doi: 10.1111/cge.12449. Epub 2014 Sep 5.
5
Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.安德森-法布里心肌病:患病率、病理生理学、诊断与治疗
Heart Fail Rev. 2015 Mar;20(2):179-91. doi: 10.1007/s10741-014-9452-9.
6
Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.法布里病的酶替代疗法:系统评价和荟萃分析。
Genet Mol Biol. 2012 Dec;35(4 (suppl)):947-54. doi: 10.1590/s1415-47572012000600009. Epub 2012 Dec 18.
7
Cardiac magnetic resonance in hypertrophic cardiomyopathy.肥厚型心肌病的心脏磁共振成像。
JACC Cardiovasc Imaging. 2011 Oct;4(10):1123-37. doi: 10.1016/j.jcmg.2011.06.022.
8
Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey.肥厚型心肌病患者中 Anderson-Fabry 病的患病率:欧洲 Anderson-Fabry 病调查。
Heart. 2011 Dec;97(23):1957-60. doi: 10.1136/heartjnl-2011-300364. Epub 2011 Sep 2.
9
Fabry disease.法布里病。
Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30.
10
Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.法布里病酶替代疗法的效果——医学文献的综合回顾。
Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75.